

Quan Yuan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/233072/publications.pdf>

Version: 2024-02-01

110
papers

6,754
citations

87888

38
h-index

69250

77
g-index

120
all docs

120
docs citations

120
times ranked

13294
citing authors

#	ARTICLE	IF	CITATIONS
1	Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. <i>Protein and Cell</i> , 2022, 13, 72-77.	11.0	6
2	5â€™ preS1 mutations to prevent large envelope protein expression from hepatitis B virus genotype A or genotype D markedly increase polymerase-envelope fusion protein. <i>Journal of Virology</i> , 2022, , JVI0172321.	3.4	0
3	A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy. <i>Antiviral Research</i> , 2022, 199, 105265.	4.1	4
4	Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells. <i>Virologica Sinica</i> , 2022, , .	3.0	0
5	Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. <i>BMC Cancer</i> , 2022, 22, 287.	2.6	17
6	A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. <i>Emerging Microbes and Infections</i> , 2022, 11, 914-925.	6.5	8
7	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 38, 110558.	6.4	15
8	Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. <i>Cell Reports</i> , 2022, 39, 110862.	6.4	9
9	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. <i>Science Bulletin</i> , 2022, 67, 1372-1387.	9.0	54
10	PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	8
11	Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. <i>Journal of Virological Methods</i> , 2022, , 114564.	2.1	7
12	New discovery of high-affinity SARS-CoV-2 spike S2 protein binding peptide selected by PhIP-Seq. <i>Virologica Sinica</i> , 2022, 37, 758-761.	3.0	0
13	SAMD4 family members suppress human hepatitis B virus by directly binding to the Smaug recognition region of viral RNA. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1032-1044.	10.5	9
14	Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. <i>National Science Review</i> , 2021, 8, nwaa291.	9.5	72
15	Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. <i>Emerging Microbes and Infections</i> , 2021, 10, 37-50.	6.5	11
16	Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase. <i>Virulence</i> , 2021, 12, 188-194.	4.4	2
17	A SCID mouse-human lung xenograft model of SARS-CoV-2 infection. <i>Theranostics</i> , 2021, 11, 6607-6615.	10.0	8
18	The prevalence of antibodies to SARS-CoV-2 among blood donors in China. <i>Nature Communications</i> , 2021, 12, 1383.	12.8	37

#	ARTICLE	IF	CITATIONS
19	Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 136.	17.1	57
20	Role of Small Envelope Protein in Sustaining the Intracellular and Extracellular Levels of Hepatitis B Virus Large and Middle Envelope Proteins. <i>Viruses</i> , 2021, 13, 613.	3.3	4
21	Lost Small Envelope Protein Expression from Naturally Occurring PreS1 Deletion Mutants of Hepatitis B Virus Is Often Accompanied by Increased HBx and Core Protein Expression as Well as Genome Replication. <i>Journal of Virology</i> , 2021, 95, e0066021.	3.4	4
22	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	56
23	Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo. <i>Nature Communications</i> , 2021, 12, 5131.	12.8	44
24	Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice. <i>Antibody Therapeutics</i> , 2021, 4, 197-207.	1.9	1
25	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. <i>Nature Communications</i> , 2021, 12, 5652.	12.8	49
26	Virus-free and Live-cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. <i>Small Methods</i> , 2021, 5, 2001031.	8.6	25
27	Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 710528.	4.8	4
28	A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. <i>Gut</i> , 2020, 69, 343-354.	12.1	34
29	Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. <i>Emerging Microbes and Infections</i> , 2020, 9, 2105-2113.	6.5	124
30	Expression Level of Small Envelope Protein in Addition to Sequence Divergence inside Its Major Hydrophilic Region Contributes to More Efficient Surface Antigen Secretion by Hepatitis B Virus Subgenotype D2 than Subgenotype A2. <i>Viruses</i> , 2020, 12, 967.	3.3	2
31	SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. <i>Emerging Microbes and Infections</i> , 2020, 9, 2076-2090.	6.5	53
32	Sustained delivery of alendronate by engineered collagen scaffold for the repair of osteoporotic bone defects and resistance to bone loss. <i>Journal of Biomedical Materials Research - Part A</i> , 2020, 108, 2460-2472.	4.0	17
33	Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. <i>European Respiratory Journal</i> , 2020, 56, 2000763.	6.7	374
34	Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development. <i>Antiviral Research</i> , 2020, 180, 104757.	4.1	6
35	Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 71, 2027-2034.	5.8	2,214
36	Identification of Kidney Transplant Recipients with Coronavirus Disease 2019. <i>European Urology</i> , 2020, 77, 742-747.	1.9	112

#	ARTICLE	IF	CITATIONS
37	Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. <i>Oncimmunology</i> , 2020, 9, 1726168.	4.6	9
38	Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro. <i>Frontiers in Pharmacology</i> , 2020, 11, 609592.	3.5	22
39	Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. <i>Nature Communications</i> , 2019, 10, 3192.	12.8	28
40	Liver chimeric mice with tupaia hepatocyte transplantation as an animal model for hepatitis B virus infection and antiviral therapy. <i>Biosafety and Health</i> , 2019, 1, 76-83.	2.7	0
41	N-acetyl cysteine-loaded graphene oxide-collagen hybrid membrane for scarless wound healing. <i>Theranostics</i> , 2019, 9, 5839-5853.	10.0	78
42	Nanobody-based sandwich reporter system for living cell sensing influenza A virus infection. <i>Scientific Reports</i> , 2019, 9, 15899.	3.3	12
43	Simultaneous <i>in situ</i> visualization and quantitation of dual antigens adsorbed on adjuvants using high content analysis. <i>Nanomedicine</i> , 2019, 14, 2535-2548.	3.3	5
44	HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation. <i>Gut</i> , 2019, 68, 2044-2056.	12.1	46
45	Robust <i>in vitro</i> assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. <i>Emerging Microbes and Infections</i> , 2019, 8, 724-733.	6.5	3
46	Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. <i>Theranostics</i> , 2019, 9, 2115-2128.	10.0	11
47	The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an <i>in vivo</i> tissue engineering chamber model. <i>Scientific Reports</i> , 2019, 9, 6035.	3.3	23
48	Extracellular Vesicles from Human Adipose-Derived Stem Cells for the Improvement of Angiogenesis and Fat-Grafting Application. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 869-880.	1.4	59
49	Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1413-1415.	4.4	8
50	An <i>in vivo</i> comparative study of the gelatin microtissue-based bottom-up strategy and top-down strategy in bone tissue engineering application. <i>Journal of Biomedical Materials Research - Part A</i> , 2019, 107, 678-688.	4.0	13
51	A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients. <i>Digestive and Liver Disease</i> , 2018, 50, 482-489.	0.9	15
52	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. <i>Journal of Hepatology</i> , 2018, 69, 286-292.	3.7	76
53	The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1779-1781.	3.3	3
54	A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves <i>in vivo</i> PK in mice and monkeys. <i>Protein and Cell</i> , 2018, 9, 130-134.	11.0	12

#	ARTICLE	IF	CITATIONS
55	Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. <i>Hepatology Research</i> , 2018, 48, E133-E145.	3.4	32
56	Collagen Functionalized With Graphene Oxide Enhanced Biomimetic Mineralization and in Situ Bone Defect Repair. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 44080-44091.	8.0	77
57	Off-the-Shelf Biomimetic Graphene Oxide-Collagen Hybrid Scaffolds Wrapped with Osteoinductive Extracellular Matrix for the Repair of Cranial Defects in Rats. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 42948-42958.	8.0	55
58	Adipose-derived mesenchymal stem cells formed acinar-like structure when stimulated with breast epithelial cells in three-dimensional culture. <i>PLoS ONE</i> , 2018, 13, e0204077.	2.5	11
59	A Chimeric Humanized Mouse Model by Engrafting the Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cell for the Chronic Hepatitis B Virus Infection. <i>Frontiers in Microbiology</i> , 2018, 9, 908.	3.5	28
60	ER stress regulating protein phosphatase 2A-B56 ¹³ , targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes. <i>Cell Death and Disease</i> , 2018, 9, 762.	6.3	29
61	Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-17.	6.5	12
62	A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway. <i>Theranostics</i> , 2018, 8, 549-562.	10.0	51
63	Bioinspired Artificial Nanodecoys for Hepatitis B Virus. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 12499-12503.	13.8	46
64	Bioinspired Artificial Nanodecoys for Hepatitis B Virus. <i>Angewandte Chemie</i> , 2018, 130, 12679-12683.	2.0	9
65	Sleeping Beauty Transposon-based System for Rapid Generation of HBV-replicating Stable Cell Lines. <i>Bio-protocol</i> , 2018, 8, e2908.	0.4	0
66	A novel toolbox for the in vitro assay of hepatitis D virus infection. <i>Scientific Reports</i> , 2017, 7, 40199.	3.3	3
67	A Smartphone-Based Genotyping Method for Hepatitis B Virus at Point-of-Care Settings. <i>SLAS Technology</i> , 2017, 22, 122-129.	1.9	12
68	Antibody-mediated immunotherapy against chronic hepatitis B virus infection. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1768-1773.	3.3	32
69	Long-term outcome of inactive and active, low viraemic HBsAg-negative hepatitis B virus infection: Benign course towards HBsAg clearance. <i>Liver International</i> , 2017, 37, 1622-1631.	3.9	51
70	A multimechanistic antibody targeting the receptor binding site potentially cross-protects against influenza B viruses. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	65
71	The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication. <i>Theranostics</i> , 2017, 7, 3090-3105.	10.0	39
72	Detection of HBV Covalently Closed Circular DNA. <i>Viruses</i> , 2017, 9, 139.	3.3	40

#	ARTICLE	IF	CITATIONS
73	An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice. <i>Experimental Animals</i> , 2016, 65, 373-382.	1.1	4
74	Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines. <i>Journal of Virological Methods</i> , 2016, 234, 96-100.	2.1	13
75	Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. <i>Science Translational Medicine</i> , 2016, 8, 352ra108.	12.4	271
76	Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. <i>Scientific Reports</i> , 2016, 6, 34531.	3.3	73
77	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. <i>Journal of Hepatology</i> , 2016, 65, 700-710.	3.7	331
78	Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera. <i>Virology Journal</i> , 2016, 13, 44.	3.4	12
79	Evaluation of a novel chemiluminescent microplate enzyme immunoassay for hepatitis B surface antigen detection. <i>Journal of Virological Methods</i> , 2016, 228, 55-59.	2.1	8
80	Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. <i>Gut</i> , 2016, 65, 658-671.	12.1	104
81	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , 2016, 65, 313-320.	12.1	112
82	Functional characterization of hepatitis B virus core promoter mutants revealed transcriptional interference among co-terminal viral mRNAs. <i>Journal of General Virology</i> , 2016, 97, 2668-2676.	2.9	8
83	On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. <i>World Journal of Hepatology</i> , 2016, 8, 1511.	2.0	7
84	Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon. <i>Theranostics</i> , 2015, 5, 218-226.	10.0	54
85	Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. <i>PLoS ONE</i> , 2015, 10, e0130209.	2.5	45
86	A lysine-rich motif in the phosphatidylserine receptor PSR-1 mediates recognition and removal of apoptotic cells. <i>Nature Communications</i> , 2015, 6, 5717.	12.8	33
87	Rapid Fluorescent Lateral-Flow Immunoassay for Hepatitis B Virus Genotyping. <i>Analytical Chemistry</i> , 2015, 87, 5173-5180.	6.5	59
88	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 197-203.	6.0	98
89	Comparison of Three Luminescent Immunoassays for Hepatitis B Virus Surface Antigen Quantification during the Natural History of Chronic Hepatitis B Virus Infection. <i>Vaccine Journal</i> , 2014, 21, 1521-1527.	3.1	4
90	Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1013-1023.	3.3	9

#	ARTICLE	IF	CITATIONS
91	Ground-glass hepatocytes co-expressing hepatitis B virus X protein and surface antigens exhibit enhanced oncogenic effects and tumorigenesis. <i>Human Pathology</i> , 2014, 45, 1294-1301.	2.0	28
92	HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. <i>Cellular and Molecular Immunology</i> , 2014, 11, 175-183.	10.5	90
93	Serum miR-483-5p as a potential biomarker to detect hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 199-207.	4.2	24
94	Hepatitis B Virus Surface Antigen (HBsAg)-Positive and HBsAg-Negative Hepatitis B Virus Infection among Mother-Teenager Pairs 13 Years after Neonatal Hepatitis B Virus Vaccination. <i>Vaccine Journal</i> , 2013, 20, 269-275.	3.1	10
95	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , 2013, 62, 182.2-184.	12.1	67
96	Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18471-18476.	7.1	75
97	Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. <i>Journal of Hepatology</i> , 2012, 57, 720-729.	3.7	158
98	Estrogen Receptor α Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor κ B. <i>Gastroenterology</i> , 2012, 142, 989-998.e4.	1.3	105
99	Evaluation of a new rapid influenza A diagnostic test for detection of pandemic (H1N1) 2009 and seasonal influenza A virus. <i>Journal of Clinical Virology</i> , 2011, 50, 153-155.	3.1	8
100	Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs. <i>Journal of Clinical Virology</i> , 2011, 52, 198-203.	3.1	41
101	Clinical characteristics and risk factors of sporadic Hepatitis E in central China. <i>Virology Journal</i> , 2011, 8, 152.	3.4	35
102	Variability of the S gene of hepatitis B virus in southeastern China. <i>Archives of Virology</i> , 2010, 155, 1951-1957.	2.1	7
103	A rapid test for the detection of influenza A virus including pandemic influenza A/H1N1 2009. <i>Journal of Virological Methods</i> , 2010, 167, 100-102.	2.1	19
104	A novel immunoassay for PreS1 and/or core-related antigens for detection of HBsAg variants. <i>Journal of Virological Methods</i> , 2010, 168, 108-113.	2.1	17
105	RNA Interference inhibits Hepatitis B Virus of different genotypes in Vitro and in Vivo. <i>BMC Microbiology</i> , 2010, 10, 214.	3.3	23
106	Molecular and Phylogenetic Analyses Suggest an Additional Hepatitis B Virus Genotype ϵ . <i>PLoS ONE</i> , 2010, 5, e9297.	2.5	123
107	Novel Double-Antigen Sandwich Immunoassay for Human Hepatitis B Core Antibody. <i>Vaccine Journal</i> , 2010, 17, 464-469.	3.1	77
108	Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors in Southeast China. <i>Journal of Clinical Microbiology</i> , 2010, 48, 357-362.	3.9	64

#	ARTICLE	IF	CITATIONS
109	Clinical Significance of Anti-HEV IgA in Diagnosis of Acute Genotype 4 Hepatitis E Virus Infection Negative for Anti-HEV IgM. Digestive Diseases and Sciences, 2009, 54, 2512-8.	2.3	36
110	Ectopic bone formation in vivo induced by a novel synthetic peptide derived from BMP-2 using porous collagen scaffolds. Journal Wuhan University of Technology, Materials Science Edition, 2007, 22, 701-705.	1.0	12